Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
AssigneeNovartis AG
InventorsGerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer
Life of this patent
Estimating the term…
Abstract
A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
Claims20
An IL-2 transcription inhibitor and 40-O-(2-hydroxyethyl)-rapamycin as a combined pharamceutical preparation in the weight ratio 2:1 to 180:1 for simultaneous, separate, or sequential use in synergistically effective amounts.
A pharmaceutical composition comprising (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin, wherein the weight ratio II is 2:1 to 180:1, in combination or association with a pharmaceutically acceptable diluent or carrier.
A method of treating or preventing an autoimmune or inflammatory condition or transplant rejection in a subject suffering from or at risk for such condition or rejection, comprising co-administering synergistically effective amounts of (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin in the weight ratio 2:1 to 180:1.
A method of treating or preventing chronic rejection of a heart, lung, or kidney transplant in a subject suffering from or at risk for such rejection, comprising co-administering together or at substantially the same time synergistically effective amounts of (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin.
A kit comprising (I) an IL-2 transcription inhibitor and (II) 40-O-(2-hydroxyethyl)-rapamycin in separate unit dosage forms, wherein said unit dosage forms are suitable for administrating I and II in synergistically effective amounts, wherein the weight ratio II is 2:1 to 180:1.
Dependencies are inferred from the claim text.